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Abstract
There is increasing interest in the use of instrumental variable analysis to overcome un-
measured confounding in observational pharmacoepidemiological studies. This is partly
because instrumental variable analyses are potentially less biased than conventional re-
gression analyses. However, instrumental variable analyses are less precise, and regula-
tors and clinicians find it difficult to interpret conflicting evidence from instrumental vari-
able compared with conventional regression analyses. In this paper, we describe three
techniques to assess which approach (instrumental variable versus conventional regres-
sion analyses) is least biased. These techniques are negative control outcomes, negative
control populations and tests of covariate balance. We illustrate these methods using
an analysis of the effects of smoking cessation therapies (varenicline) prescribed in pri-
mary care.
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Key Messages
• Clinicians and regulators struggle to interpret conflicting evidence from instrumental variable compared with conven-
tional regression analysis.
• The relative bias of these methods can be assessed using negative control outcomes, negative control populations
and tests of covariate balance.
• Researchers could report bias component plots with confidence intervals to robustly assess the relative bias due to
each covariate.
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Introduction
Unmeasured or residual confounders can bias the results
from observational studies of routinely collected data. For
example, in pharmacoepidemiological studies, treatment
choice is influenced by a number of factors (e.g. comorbid-
ities, socioeconomic position, education) that relate to out-
comes, but are often not perfectly recorded or measurable
in the sorts of electronic medical records data that are used
in such analyses. This ‘confounding by indication’ means
that the observed association of treatment with an out-
come is often an unreliable indicator of any causal adverse
or beneficial effects of the treatment of interest.
This problem of ‘confounding by indication’ is illustrated
in Figure 1, where the outcome Y is caused by the exposure
X and the unobserved or residual confounder C. The associ-
ation of the exposure with the outcome will be biased be-
cause they are both caused by a confounding factor C.
Confounding by indication affects the likelihood of receiving
the prescription and having the outcome, independently of
the true causal effects of the prescription. Therefore using
methods which adjust for confounding, such as multivariable
adjusted regression or propensity score regression, when the
confounding factors are either not measured or not measured
sufficiently precisely can give biased estimates.1
Instrumental variable analysis is a statistical approach
that can theoretically overcome these problems.2–7
Instrumental variables are defined by three assumptions:
A) they are associated with the exposure of interest; B)
they are not associated with confounding factors; and C)
they have no direct effect on the outcome of interest.8,9
These assumptions are illustrated in Figure 1, where the in-
strument variable Z only affects the prescription X.
We can obtain a valid estimate of the effects of the ex-
posure on the outcome using the so-called Wald estimator
which identifies the effects of treatment on the risk differ-
ence scale. Denote the sub-sample averages of Y and X by
y1 and x1 when Z ¼ 1 and by y0 and x0 when Z ¼ 0. The
Wald estimator is then given by:
w^ ¼ y1  y0
x1  x0
and is consistent for the estimand:
w ¼ E½YjZ ¼ 1  E½YjZ ¼ 0
E½XjZ ¼ 1  E½XjZ ¼ 0
In a pharmacoepidemiological study of the effects of
prescribed drugs, physicians’ preferences for particular
drugs are potential instruments for the prescriptions they
issue to their patients.7 This is because physicians’ prefer-
ences for medications affect the drugs they issue
(assumption i), but the preferences themselves will not ne-
cessarily be related to their patients’ pre-existing comor-
bidities (assumption ii) and will not necessarily directly
affect their patients’ outcomes (assumption iii). Patients
generally register with their GP long before they are pre-
scribed treatments, so their choice of GP is unlikely to be
related to their GP’s preference for a specific medication,
thus ensuring that using prescribing preference as an in-
strument for treatment received does not violate assump-
tions i and ii. We cannot directly measure physicians’
preferences from prescribing databases, so preferences are
‘latent variables’ indicated by Z in Figure 2. In the analysis
of the effects of smoking cessation therapies in primary
care described here, we use the physicians’ prescriptions of
varenicline or nicotine replacement products to their previ-
ous patients as proxies for their preferences. Recent studies
have found that physicians’ prescribing preferences could
potentially be a valid instrument for prescribing of non-
steroidal anti-inflammatory drugs (NSAIDs), antidepres-
sants, smoking cessation medication and anti-psych-
otics.7,10–20 However, a study using data from German
health insurance records found that physicians’ preferences
are not always valid for NSAIDs.21 Therefore the validity
of physicians’ prescribing preferences as instruments is
context-dependent and needs to be assessed in new appli-
cations or data sources.
As the use of instrumental variable methods is relatively
novel in epidemiology, we currently do not have sufficient
information to advise policy makers and regulators about
the specific situations where instrumental variable analysis
is likely to provide a less biased estimate of the causal effect
of a drug than conventional regression analyses. Here we
describe how negative control outcomes, negative control
populations and bias component plots can be used to assess
Figure 1. Directed acyclic graph of outcome Y, prescription X, the in-
strumental variable Z and a potentially unmeasured confounder C (left).
Each variable’s directed effects (edges) are denoted by arrows.
Figure 2. Directed acyclic graph of an analysis using the physicians’
prescriptions to their previous patients, Z* as a proxy for their prefer-
ences, the true underlying instrument, Z, which is a latent variable. The
exposure, outcome and confounder are indicated as X, Y and C,
respectively.
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the validity of instrumental variables for dealing with con-
founding by indication.22
Methods
In this section, we describe three approaches to assess the
relative bias of conventional and instrumental variable esti-
mates by using: i) negative control outcomes; ii) negative
control populations; and iii) bias component plots.
Negative control outcomes
One way to evaluate whether the instrumental variable as-
sumptions hold is to investigate whether the instrumental
variables are associated with negative control outcomes
likely to be affected by the same confounders as the out-
come of interest, but that are unlikely to be directly af-
fected by the exposure. These may be: (i) outcomes for
which we believe there can be no plausible effect of the ex-
posure; or (ii) records indicating whether an outcome of
interest occurred before the patient was exposed to the
treatment of interest (see Figure 3). If the instrumental vari-
able is associated with a negative control outcome, then
this suggests that there may be residual confounding and
that assumption B of the instrumental variable analysis has
been violated. The association of the instrument and the
negative control outcome can be tested using linear regres-
sion. It is important to choose a negative control outcome
that is affected by the same confounders as the outcome of
interest, and which has sufficient variation to have ad-
equate power.23 If a rare negative control outcome is used,
then plots comparing the conventional linear and instru-
mental variable regression estimates would have wide con-
fidence intervals and are likely to be uninformative.24
The negative control outcome here can be a different
diagnosis from the outcome of interest which occurs after
prescription but is unlikely to be affected by treatment:
an example in the case of varenicline is a urinary tract
infection (see Figure 4). This is likely to be a suitable
negative control outcome because a smoking cessation
drug prescription is unlikely to be affected by a patient’s
risk of developing a urinary tract infection. However,
patients prescribed varenicline (as we will see) are gener-
ally healthier than those prescribed nicotine replacement
therapy. Therefore they are likely to have a lower risk
of urinary tract infection prior to prescription. Thus,
urinary tract infections are affected by the same con-
founders, but are unlikely to be caused by varenicline.
An example of a negative control outcome that is af-
fected by treatment but occurred before the patient was
prescribed treatment, could be a diagnosis of schizophre-
nia in the 6 months before the first smoking cessation
prescription.
Negative control populations
Another possible method to evaluate the instrumental vari-
able assumptions is to use a negative control population. A
negative control population has a similar confounding
structure as the population of interest but was not exposed
to the treatment of interest. In the context of physician pre-
scribing preferences, the negative control population com-
prises patients that consulted with a GP who recently
Negative control outcomes: 
Negative control population: 
Time 
Attended GP A but was not 
prescribed smoking 
cessation therapy
Prescribed smoking 
cessation therapy by GP A 
Outcome 3 
Negative control 
outcome 1 
Negative control 
outcome 2 
Patient A 
Patient B 
Figure 3. Proposed negative control outcomes and negative control populations.
Rate of 
urinary tract 
infection 
Confounders
Physicians’ 
preferences for 
varenicline 
Physicians’ 
previous 
prescription Actual 
prescription 
issued 
Figure 4. Using urinary tract infections as a negative control outcome
to investigate the effects of prescribing varenicline.
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prescribed the medication of interest to another patient,
but the negative control patient attended the GP for an un-
related reason and were not themselves prescribed the
medications of interest (see Figure 3). In the case of smok-
ing cessation therapies, these patients may not themselves
be smokers. If the GP’s preferences have no direct effect
on their patients’ outcomes then the instrumental vari-
able, the physicians’ previous prescription, should not be
associated with the outcomes in the negative control
population. This is because a GP’s preferences for smok-
ing cessation medications cannot directly affect the out-
comes of patients who were not prescribed smoking
cessation medications. If the proposed instrument is asso-
ciated with any outcomes in the negative control popula-
tion, this suggests that it may be operating through
another mechanism.
Bias component plots
Historically, studies using instrumental variables have re-
ported tables of covariate balance across the exposure and
the proposed instrument.25 Under the assumption that the
structure of the observed confounding is similar to the unob-
served confounding, we can potentially make inferences
about the relative bias of the conventional linear and instru-
mental variable regression due to residual confounding. The
confounders of the exposure-outcome relationship are not
necessarily the same as the confounders of the instrument-
outcome relationship. There is a substantial literature that
describes methods to investigate the relative bias due to
observed confounders. Brookhart and Schneeweiss (2007)
described how to use the ‘prevalence difference ratio’ to in-
vestigate the relative bias.26 This is the ratio of the difference
in an observed dichotomous confounder across values of the
exposure and values of the instrument. However, this statis-
tic does not directly account for the strength of the instru-
ments. Brookhart and Schneeweiss conclude that if the
prevalence difference ratio is smaller than the strength of the
instrument, then the instrumental variable results are likely
to have a lower asymptotic bias. Baiocchi and colleagues
(2014) recommend generating a single statistic by dividing
the prevalence difference ratio by the strength of the instru-
ment to calculate what they term the ‘bias ratio’.24 Jackson
and Swanson (2015) illustrated how simple plots of the asso-
ciations of instrument and exposures with observed con-
founders can be misleading about the relative bias of
instrumental variable and conventional linear regression.27
These methodological papers agree that one can only com-
pare the relative bias of the two approaches if the fact that
the instrument only explains a small proportion of the vari-
ation in the exposure is accounted for.24,26,27 To see why,
compare the following expression for bias of the linear re-
gression if the covariate C is omitted:
biasðOLSÞ=bC ¼ E½CjX ¼ 1  E½CjX ¼ 0
.where bC is the direct effect of C on the outcome. The bias
in the Wald estimator if covariate C is omitted is:
biasðIVÞ=bC ¼
E½CjZ ¼ 1  E½CjZ ¼ 0
E½XjZ ¼ 1  E½XjZ ¼ 0
For comparisons, we normalize bC ¼ 1. Jackson and
Swanson argue that these estimated biases should be pre-
sented graphically using bias plots to aid interpretation.27
Bias components without confidence intervals are
uninformative
One limitation of these methods is that they ignore sam-
pling variability, so the calculated differences could simply
be due to chance. Furthermore, sampling variability will
have a larger impact on the instrumental variable results
because the instrumental variable estimates are less precise.
Therefore, sampling variability must be taken into account
when assessing bias. The simplest way to do this is to pre-
sent confidence intervals around both the treatment and in-
strumental variable biases components and present a
statistical test for differences between the terms.
Under the assumption of a constant effect of treatment,
we can test whether the linear regression or instrumental
variable bias component is bigger using a modified
Hausman test. This test can be estimated using generalized
method of moments; see online code repository for statis-
tical code for this test at [https://github.com/nmdavies/vare
nicline-cprd-neg-control/]:
ðb^iv  b^olsÞ
sqrt

va^rðb^iv  b^olsÞ
  Nð0; 1Þ
where b^ols and b^iv are the ordinary least squares regression
and instrumental variable regression estimates of the bias
component terms. The null hypothesis of this test is that
there is no difference between the linear regression and in-
strumental variable bias components. The alternative hy-
pothesis is that there are differences. If there is little
evidence of systematic differences between the instrumen-
tal variable and linear regression bias components, then we
cannot say with any certainty which is bigger and it is diffi-
cult to draw any strong conclusions about the likely rela-
tive bias of the conventional linear and instrumental
variable estimators. This is because any differences in the
bias components could just be due to sampling variability,
not differences in the true underlying distributions in the
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population or the true underlying distribution of unob-
served confounders. Covariates which have systematic dif-
ferences between the conventional linear and instrumental
variable regression bias components are informative about
the relative bias. We can illustrate this point using a simple
simulation of a hypothetical analysis. Consider the follow-
ing data-generating process:
v;w;u  Nð0;1Þ
The proposed instrument is distributed as an independ-
ent dichotomous variable. Therefore the exclusion restric-
tion is valid:
z  bernoullið0:2Þ
Without loss of generality, assume that we have 10 po-
tential (but not true) dichotomous confounders, j ¼ 1; : :;10:
cj  bernoullið0:2Þ
Let the dichotomous exposure equal:
x ¼ 1ðzcþ u þ w > dÞ;
where 1ðaÞ ¼ 1 if a and 0 otherwise, and c is the strength of
the effect of the instrument on the exposure, we set c ¼ 0:5.
We set the parameter d to ensure that Pr ½x ¼ 1 ¼ 0:2. The
outcome is a continuous variable equal to:
y ¼ xbþ uþ v
Conventional linear regression will suffer from bias due
to the confounder u. We set the effect of the exposure,
b ¼ 0:5, and N ¼ 10;000. The left panel of Figure 5 pre-
sents bias components without confidence intervals as
recommended by Jackson and Swanson (2015).27 From
this figure, we would erroneously conclude that the instru-
mental variable analysis has larger bias components than
conventional regression,n as the instrumental variable bias
components are larger. However, in this simulated ex-
ample, we know for certain that the instrumental variable
analysis is asymptotically unbiased. The right panel of
Figure 5 adds confidence intervals around the point esti-
mates. The confidence intervals make it clear that there are
no systematic and detectable differences in the bias compo-
nents. Therefore bias component plots are not interpret-
able without confidence intervals.
Selecting on (non-) treatment
Swanson and colleagues have suggested, using a simulated
data-generating process, that instrumental variable studies
can suffer from collider bias if analyses are restricted to pa-
tients who received a specific set of treatments, or if un-
treated patients are excluded.29 An example might be a
study of smoking cessation treatment that ignored all
smokers who chose not to take any medication. At present,
it is not clear how pervasive this bias is in empirical phar-
macoepidemiological studies. We can use the simulation
described by Swanson and colleagues to investigate
whether this bias is likely to be detectable using the meth-
ods described above. We modified their simulation to have
a proxy (measured) confounder which had only a weak
correlation with the true confounder (r2¼ 0.01) and found
that if we restricted the analysis to treated patients, the in-
strumental variable bias component was detectable and an
order of magnitude larger than the linear regression bias
component. Therefore, whereas this bias is possible in em-
pirical pharmacoepidemiological studies, it is likely to be
Figure 5. Bias component plots (left), are not informative without confidence intervals (right). Simulated bias component terms for 10 potential con-
founders (indicated c1 to c10) for the actual prescription () and proposed instrument ( ).
Simulation of 10 potential confounders when the instrument is valid. Using bias component plots alone we would erroneously conclude that the in-
strumental variable bias components were systematically larger than the linear regression bias components. Once we add confidence intervals to
the point estimates, it becomes clear that the differences in components are entirely consistent with chance. There is no evidence from these poten-
tial confounders that the linear and instrumental variable regression bias component differ.
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detected by the statistics described above. The full statis-
tical code of this analysis is available online at [https://
github.com/nmdavies/varenicline-cprd-neg-control/].
Application of negative controls and bias
plots
Study design and population
We illustrate the use of negative controls and bias plots
using a sample from the Clinical Practice Research
Datalink (CPRD) in which we investigated the effects of
varenicline on suicide and self-harm, and depression.18 We
were concerned that multivariable adjusted estimates of
the effect of varenicline would suffer from residual con-
founding due to healthy user bias. Patients prescribed vare-
nicline were healthier in almost all ways we could
measure, and they were potentially healthier in ways we
could not measure as well. This means we may underesti-
mate the effect of varenicline on adverse outcomes. We
used conventional multivariable adjusted regression and an
instrumental variable analysis using physicians’ prescribing
Table 1. Description of baseline confounders of patients prescribed varenicline or nicotine replacement products
Varenicline Nicotine replacement products
N¼52981 N¼122159
(%) SD (%) SD
Male 49.3 45.9
Age (years)a 44.3 13.1 46.1 15.6
Prescribed in 2007 12.7 25.4
Prescribed in 2008 19.4 17.7
Prescribed in 2009 19.1 17.3
Prescribed in 2010 20.1 14.7
Prescribed in 2011 18.4 12.5
Prescribed in 2012 10.3 7.1
Number of GP visits in previous yeara 6.3 8.9 12.0 11.2
Diagnoses in the previous year
Autism 0.0 0.0
Bipolar 0.0 0.2
Current smoker 61.4 61.6
Dementia 0.0 0.1
Depression 3.8 6.5
Eating disorder 0.0 0.1
Hyperkinetic disorder 0.0 0.0
Learning disability 0.0 0.1
Neurotic disorder 2.0 3.4
Other behavioural disorder 0.0 0.0
Personality disorder 0.0 0.1
Schizophrenia 0.0 0.3
Alcohol misuse 0.9 1.7
Probable self-harm 0.0 0.0
Drug misuse 0.1 0.3
Fractures 1.3 1.8
Any psychiatric illness 6.0 10.5
Chronic disease 7.7 11.2
Prescriptions in the previous year
Antidepressant 17.0 26.5
Antipsychotic 2.9 6.4
CNS stimulant 0.0 0.1
Dementia medication 0.0 0.0
Hypnotic anxiolytic 4.7 7.0
Lithium 0.1 0.4
This sample was larger than used Thomas and colleagues (2013) as in this study we also included patients who attended general practices that were not linked
to the Hospital Episodes Statistics data.18
aContinuous variables, mean and standard deviation (SD) reported.
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3 months
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Absolute risk difference in incidence
Less common with varenicline More common with varenicline  
Figure 6. Negative control outcome: difference in the incidence of urinary tract infections in the four years after smoking cessation treatment for the
index patients by actual prescription () and the proposed instrument ( ).
Horizontal lines indicate robust confidence intervals for each prescription. There is little evidence of differences in the prescribing history when the
confidence intervals span zero on the axis.
Table 2. Association of proposed instrument and outcomes of other patients who saw the GP on the same day as they issued a
smoking cessation therapy to an index patient (n¼ 101861)
Robust linear regression
Risk
difference*100
95% confidence interval
Lower Upper
Male 0.77 0.02 1.52
Age (years)a 0.35 0.65 0.05
Number of GP visits in previous yeara 0.35 0.61 0.08
Diagnoses in the previous year
Autism 0.00 0.02 0.02
Bipolar 0.01 0.05 0.03
Current smoker 0.28 0.51 1.07
Dementia 0.00 0.12 0.13
Depression 0.04 0.42 0.35
Eating disorder 0.02 0.05 0.02
Hyperkinetic disorder 0.00 0.01 0.01
Learning disability 0.01 0.06 0.05
Neurotic disorder 0.56 0.29 0.84
Other behavioural disorder 0.01 0.04 0.01
Personality disorder 0.02 0.03 0.07
Schizophrenia 0.00 0.05 0.05
Alcohol misuse 0.08 0.06 0.22
Probable self-harm 0.01 0.01 0.00
Drug misuse 0.03 0.04 0.11
Fractures 0.03 0.15 0.21
Any psychiatric illness 0.36 0.10 0.81
Chronic disease 0.12 0.34 0.59
Prescriptions in the previous year
Antidepressant 0.44 0.28 1.17
Antipsychotic 0.17 0.18 0.52
CNS stimulant 0.02 0.02 0.05
Dementia medication 0.00 0.12 0.13
Hypnotic anxiolytic 0.02 0.40 0.35
Lithium 0.07 0.01 0.16
Robust standard errors clustered by physician reported.
*Mean differences reported. Each outcome was defined as an event in the year after the index prescription.
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preferences for varenicline versus nicotine replacement
therapy as an instrument.18 A description of the study co-
hort characteristics is presented in Table 1. Physicians who
prescribed varenicline to their previous patient were 24
percentage points [95% confidence interval (CI): 23, 25]
more likely to prescribe varenicline to their subsequent pa-
tients than physicians who previously prescribed nicotine
replacement therapy (partial F-statistic¼ 1011.5). The large
value of the partial F-statistic found here indicates that the
instrument is strongly associated with the exposure.
We investigated whether varenicline was associated
with a negative control outcome, urinary tract infections,
as smoking cessation treatment is unlikely to affect the in-
cidence of urinary tract infections. The conventional
regression analysis suggests that patients prescribed vareni-
cline were less likely to be subsequently diagnosed with a
urinary tract infection (Figure 6). However, the instrumen-
tal variable analyses provided little evidence that vareni-
cline caused urinary tract infections (Figure 6). The
simplest explanation of these results is that the conven-
tional regression analysis suffers from residual confound-
ing, and the instrumental variable results do not (i.e. our
instrument is not associated with potential confounders).
We also investigated whether physicians’ preferences had
any effects in a negative control population–individuals
prescribed an antidepressant who consulted with a phys-
ician on the same day that the GP issued a smoking cessa-
tion medication to another patient. We found little
Table 3. Estimates of the bias components for linear regression (equation 1) and instrumental variables (equation 2), and test
for difference between the biases
Linear regression bias component Instrumental variable bias component Test for
differenceb
100*risk
difference
Confidence interval 100*risk
difference
Confidence interval
N¼175,140 Lower Upper Lower Upper P-values
Male 3.06 2.50 3.63 1.05 1.32 3.42 0.08
Age (years)* 1.66 1.84 1.49 0.65 1.38 0.08 0.004
Number of GP visits in previous year* 5.82 5.99 5.65 4.88 5.47 4.29 5.84E-04
Diagnoses in the previous year
Autism 0.01 0.02 0.00 0.03 0.07 0.01 0.47
Bipolar 0.17 0.20 0.14 0.09 0.25 0.06 0.35
Current smoker 0.33 0.98 0.33 3.34 0.70 5.98 0.002
Dementia 0.13 0.16 0.10 0.06 0.08 0.20 0.01
Depression 2.57 2.83 2.31 1.60 2.73 0.47 0.07
Eating disorder 0.03 0.05 0.00 0.03 0.14 0.08 0.98
Hyperkinetic disorder 0.02 0.03 0.00 0.09 0.13 0.04 2.11E-04
Learning disability 0.11 0.13 0.08 0.09 0.22 0.04 0.79
Neurotic disorder 1.25 1.43 1.07 0.07 0.92 0.77 0.004
Other behavioural disorder 0.01 0.03 0.00 0.00 0.07 0.08 0.65
Personality disorder 0.09 0.12 0.07 0.03 0.16 0.11 0.34
Schizophrenia 0.25 0.29 0.22 0.32 0.51 0.14 0.47
Alcohol misuse 0.80 0.92 0.68 0.14 0.41 0.70 6.64E-04
Probable self-harm 0.00 0.01 0.00 0.00 0.03 0.03 0.90
Drug misuse 0.24 0.29 0.18 0.22 0.47 0.02 0.90
Fractures 0.54 0.67 0.41 0.30 0.87 0.28 0.39
Any psychiatric illness 4.23 4.54 3.92 1.51 2.89 0.13 5.00E-05
Chronic disease 3.50 3.85 3.16 0.60 0.87 2.07 6.50E-09
Prescriptions in the previous year
Antidepressant 9.68 10.17 9.20 3.15 5.15 1.16 1.06E-11
Antipsychotic 3.54 3.76 3.32 1.52 2.55 0.49 7.78E-05
CNS stimulant 0.05 0.08 0.02 0.01 0.12 0.13 0.39
Dementia medication 0.04 0.06 0.03 0.01 0.09 0.07 0.37
Hypnotic anxiolytic 2.34 2.60 2.08 0.99 2.13 0.14 0.01
Lithium 0.32 0.37 0.28 0.37 0.60 0.15 0.64
*Mean differences reported. Robust standard errors allowing for general form heteroskedasticity clustered on physician.
bTest for differences between the conventional regression and instrumental variable regression bias is ðb^ iv  b^olsÞ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
va^rðb^ iv  b^olsÞ:
q
8 International Journal of Epidemiology, 2017, Vol. 0, No. 0
evidence that the proposed instrument was associated with
a range of outcomes in this population (Table 2). As there
is little evidence that physicians’ preferences for prescribing
varenicline directly affected their patients’ outcomes, this
provides reassurance that they are potentially valid instru-
ments (i.e. unconfounded).
The differences in baseline confounders for the actual
exposure (prescription of varenicline rather than nicotine
replacement therapy) and the proposed instrument (GP’s
prescribing preference for varenicline versus nicotine re-
placement therapy) are shown in Table 3 and are presented
in Figures 7–9. These results suggest that the instrumental
Figure 7. Bias component plots: difference in patient’s age and the
number of consultations in the previous year by actual exposure ()
and proposed instrument ( ). The figures for the instrumental variable
results account for the strength of the instrument as described in
Jackson and Swanson (2015).27
The horizontal lines indicate robust confidence intervals for each pre-
scription. There is little evidence of differences in the prescribing history
when the confidence intervals span zero on the axis.
Figure 8. Bias component plots: difference in patients’ diagnoses in the previous year by actual exposure () and proposed instrument ( ). The fig-
ures for the instrumental variable results account for the strength of the instrument as described in Jackson and Swanson (2015).27 The horizontal
lines indicate robust confidence intervals for each prescription. There is little evidence of differences in the prescribing history when the confidence
intervals span zero on the axis.
Figure 9. Bias component plots: difference in patients’ prescriptions
received in the previous year by actual prescription () and proposed
instrument ( ). The figures for the instrumental variable results account
for the strength of the instrument as described in Jackson and Swanson
(2015).27
The horizontal lines indicate robust confidence intervals for each pre-
scription. There is little evidence of differences in the prescribing history
when the confidence intervals span zero on the axis.
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variable ( ) analysis would be less biased from these observed
confounders than the conventional regression analysis ().
This is because the instrumental variable bias terms are
smaller than the conventional regression bias terms for num-
ber of consultations, age, diagnosis of a neurotic disorder, al-
cohol misuse, any psychiatric illness, chronic disease,
prescription of antidepressants, antipsychotics and hypnotics.
There are some caveats to these approaches. First, we
cannot directly measure all confounders so must be cau-
tious in assuming that the approaches provide conclusive
proof that the instrument is valid. Second, using these
approaches for one exposure-outcome association may not
generalize to the instruments for other treatments. Third,
the bias component terms assume a constant treatment ef-
fect. This means it is unclear whether these bias terms pro-
vide valid inferences about the relative bias when there are
binary outcomes or heterogeneous treatment effects.
Conclusion
We have demonstrated how negative control populations,
negative control outcomes and covariate balance tests,
when appropriately applied, can be used to investigate the
relative biases of instrumental variable analysis and con-
ventional regression. These approaches could be useful to
researchers for interpreting evidence from studies reporting
and comparing conventional and instrumental variable
analysis, and ultimately improve the strength of the evi-
dence provided to clinicians and policy makers.
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Glossary
• Instrumental variable: a variable associated with the treatment of interest, but independent of confounding factors
and having no direct effect on the outcome.
• Physicians’ prescribing preferences: the physicians’ preferences for prescribing one medication over another. It is not
normally possible to directly measure physicians’ preferences, so most studies use the prescription they issued to
their previous patients as a proxy.
• Negative control outcome: an outcome which the researcher believes should not be affected by the exposure or the
proposed instrumental variable.
• Negative control population: a population in which the researcher believes the exposure or instrumental variable will
not affect or be related to the outcome.
• Bias component plot: a graph depicting the relative bias of conventional regression and instrumental variable regres-
sion using observed covariates.
• Latent variable: a variable in a statistical model which is unobserved.
• Collider bias: if a variable, ‘a collider’, is caused by both the exposure and the outcome and is conditioned or selected
on, then the conditional exposure-outcome association will be biased. This bias is referred to as collider bias.
• Confounding by indication: indications for treatment, such as blood pressure or cholesterol level, affect the likelihood
of treatment with specific medications and can also affect the likelihood of an outcome. Thus indications confound
the observed association of the treatment and outcomes, and hence this association is likely to be a biased estimate
of the causal effects of treatment.
• Hausman test for endogeneity: test for differences between the conventional regression and instrumental variable
results.
• Partial F-test: test used to evaluate the strength of the association between the instrumental variable(s) and the ex-
posure, analogous to sample size in a randomized trial.
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